A new study found that breast implants are linked to an increased risk of this rare type of cancer.
A new international study found that night shift work significantly increases the risk of developing common cancers in women.
The U.S. Food and Drug Administration has approved the use of the intravenous drug TRISENOX (Teva Pharmaceutical Industries Ltd.) in combination with tretinoin for first line treatment of adult patients who have been newly-diagnosed with low-risk APL.
The U.S. Food and Drug Administration has approved a new breast cancer treatment machine that uses gamma rays to target tumors without harming healthy tissue.
The National Comprehensive Cancer Network has issued updated guidelines for Hodgkin lymphoma, which focus on the management of HL using existing treatments and the need for long-term follow-up after treatment completion.
An old treatment paradigm may be killing women.
Which combination provides the best outcome for high-risk NSCLC? Here's the answer.
Things are looking up for ALK-positive NSCLC patients, thanks to the recent FDA approval of Alecensa (alectinib), a highly selective ALK inhibitor that was shown to reduce the risk of disease worsening or death by 47% compared with crizotinib.
One group of breast cancer patients improves significantly following treatment with Eribulin.
The NEJM published results from a phase III trial showing that osimertinib exhibited longer progression-free survival and could be a new first-line treatment for patients with untreated EGFR-mutated NSCLC.
The U.S. Food and Drug Administration (FDA) has released a warning reminding patients that thermography should not replace mammography for breast cancer screening.
A new study found that adverse effects were the most common reason for patients with chronic myeloid leukemia to discontinue use of tyrosine kinase inhibitors.
A new study found that a combination of everolimus and fulvestrant doubled progression-free survival in these patients compared to fulvestrant alone.
Patients can take TKIs for the rest of their lives. But do they need to?
Measuring tumor-specific mutations in blood and urine samples may be useful for monitoring response to treatment and identifying early signs of metastases after radical cystectomy in patietns with advanced bladder cancer, according to researchers.